SOPHiA GENETICS CMO sells shares for tax withholding

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu disposed of 4,731 Ordinary Shares in open-market sales tied to tax obligations.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu disposed of 4,731 Ordinary Shares in open-market sales tied to tax obligations. On April 8, he sold 2,800 shares at a weighted average of $4.8370, and on April 9 he sold 1,931 shares at a weighted average of $4.7393.

The footnotes state these sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, meaning they were not discretionary trades. After these transactions, Menu directly holds 276,721 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 4,731 shares

Net Sell 2 txns

Insider Menu Philippe

Role Chief Medical Officer

Sold 4,731 shs ($23K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,931	$4.7393	$9K
Sale	Ordinary Shares	2,800	$4.837	$14K

Holdings After Transaction: Ordinary Shares — 276,721 shares (Direct)

Footnotes (3)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.78 to $4.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.655 to $4.86, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold April 8, 2026: 2,800 shares Price April 8, 2026: $4.8370 per share Shares sold April 9, 2026: 1,931 shares +3 more

6 metrics

Shares sold April 8, 2026 2,800 shares Open-market sale of Ordinary Shares at weighted average $4.8370

Price April 8, 2026 $4.8370 per share Weighted average sale price for 2,800 Ordinary Shares

Shares sold April 9, 2026 1,931 shares Open-market sale of Ordinary Shares at weighted average $4.7393

Price April 9, 2026 $4.7393 per share Weighted average sale price for 1,931 Ordinary Shares

Total shares sold 4,731 shares Net shares disposed across two open-market tax-related sales

Shares held after transactions 276,721 shares Direct Ordinary Share holdings following both April 2026 sales

Key Terms

restricted stock units, Rule 10b5-1 trading plan, weighted average price, open market, +1 more

5 terms

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market financial

"Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

tax withholding obligations financial

"sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SOPHiA GENETICS (SOPH) Chief Medical Officer disclose in this Form 4?

The filing shows Chief Medical Officer Philippe Menu disposed of 4,731 Ordinary Shares in two open-market transactions. These sales covered tax withholding obligations from recently vested restricted stock units and were executed under a pre-established Rule 10b5-1 trading plan.

How many SOPHiA GENETICS (SOPH) shares did the CMO sell and at what prices?

Philippe Menu sold 2,800 Ordinary Shares at a weighted average price of $4.8370 and 1,931 shares at a weighted average price of $4.7393. The trades occurred on April 8 and April 9, 2026, respectively, in open-market transactions.

Why were Philippe Menu’s SOPHiA GENETICS (SOPH) share sales executed?

The sales were made solely to satisfy tax withholding obligations from the vesting of restricted stock units on April 2 and 3, 2026. The transactions are characterized as mechanistic tax-related disposals rather than discretionary investment decisions by the Chief Medical Officer.

Were SOPHiA GENETICS (SOPH) CMO share sales under a Rule 10b5-1 plan?

Yes. The footnotes state the sales were effected under a pre-established Rule 10b5-1 trading plan adopted by Philippe Menu. Such plans pre-schedule trades, indicating these transactions were not timed at his discretion but followed preset instructions for tax obligations.

How many SOPHiA GENETICS (SOPH) shares does the CMO hold after these transactions?

After completing the two tax-related sales totaling 4,731 shares, Philippe Menu directly holds 276,721 Ordinary Shares. This remaining position provides context, showing the disposals were relatively small compared with his overall direct shareholding in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/10/2026 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/08/2026		S		2,800(1)	D	$4.837(2)	278,652	D
Ordinary Shares	04/09/2026		S		1,931(1)	D	$4.7393(3)	276,721	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.78 to $4.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.655 to $4.86, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)